Article info

Download PDFPDF

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Authors

  1. Correspondence to Dr James R Seibold, Scleroderma Research Consultants, LLC, Aiken, SC 29803, USA; jamesrseibold{at}gmail.com
View Full Text

Citation

Seibold JR, Maher TM, Highland KB on behalf of the SENSCIS trial investigators, et al
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Publication history

  • Received March 12, 2020
  • Revised June 15, 2020
  • Accepted June 29, 2020
  • First published August 5, 2020.
Online issue publication 
October 12, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.